By Sheeba M. | April 24, 2026
Cannabis Q1 Earnings Preview: What Wall Street Expects
As cannabis earnings season heats up, institutional investors are laser-focused on one metric: unit economics. After a brutal 2024 where oversupply crushed margins across cultivation and retail, operators are proving they can scale profitably in a maturing market.
This quarter, the Street expects Curaleaf Holdings and Trulieve Cannabis to report margins stabilizing around 30-35% in their core markets—a significant recovery from 2024 lows. What matters most: are they defending territory against smaller competitors, or is consolidation opening new margin opportunities?
The Consolidation Play
Despite federal legalization remaining stalled, state-level M&A is accelerating. The operators consolidating regional chains are creating scale advantages that smaller competitors can’t match. Expect guidance commentary around acquisition pipelines—any signals of accretive deals could drive outperformance.
Greenrose Acquisition Corp and other SPACs continue repositioning post-legalization. Watch for any major announcements around license conversions or market exits this week.
International Exposure
Operators with Canadian or European exposure—like Ayr Wellness—are benefiting from higher margins and premium pricing in those markets. Look for commentary on geographic diversification and growth strategies beyond the U.S. This is where next-generation cannabis valuations will be built.
Sources
- Reuters Cannabis Coverage — Latest earnings schedules and market updates
- Yahoo Finance — Real-time stock tracking and analyst consensus
- U.S. Securities and Exchange Commission — Official filings and earnings transcripts
Track cannabis stocks with the Weedstock Real-Time Tracker